Targeted Genetics Enhances Inflammatory Arthritis Product Development Platform
2006年6月5日 - 8:45PM
ビジネスワイヤ(英語)
Targeted Genetics Corporation (Nasdaq:TGEND) reported new data from
studies designed to enhance the company's ability to develop novel
therapeutic products for the treatment of inflammatory arthritis.
The data, presented in two abstracts at the American Society of
Gene Therapy (ASGT) 2006 Annual Meeting, demonstrate that
adeno-associated virus type 2 (AAV2), the delivery vector used in
the company's clinical development candidate tgAAC94 supports
sustained transgene expression for at least one year following a
single intra-articular administration (abstract #983), and abstract
#578 describes the potent anti-inflammatory activity achieved using
an AAV vector based on an alternate serotype, AAV1. These studies
provide important information that may be used to optimize the
safety and efficacy of AAV-based therapeutic products for the
treatment of inflammatory arthritis and, potentially, other
diseases. "As reported this week at ASGT, we are seeing early but
promising results in our Phase I/II trial of tgAAC94, our lead
anti-inflammatory product candidate, administered directly to
joints," said H. Stewart Parker, president and chief executive
officer of Targeted Genetics. "Preclinical data also presented this
week demonstrate that a single administration of AAV-TNFR:Fc
results in expression of TNFR:Fc for more than a year. This
suggests that tgAAC94 may require infrequent administration and
thus enable patient-friendly dosing schedules." Ms. Parker further
comments, "These studies are important because AAV-1 based vectors
deliver genes into muscle cells very efficiently resulting in the
muscle cells secreting proteins produced from those genes into the
blood stream. Thus, intramuscular administration of AAV vectors may
provide a new paradigm for systemic therapy for inflammatory
arthritis and other chronic diseases that are currently treated
with therapeutic protein products. This approach complements our
efforts to develop tgAAC94 as a locally administered
anti-inflammatory therapy and also opens the door to developing a
number of next-generation versions of currently approved protein
therapies." About tgAAC94 tgAAC94 is being developed as a potential
supplement to systemic anti-TNF-alpha protein therapy for use in
patients with inflammatory arthritis who have one or more joints
that do not respond to systemic protein therapy. The product
candidate uses Targeted Genetics' recombinant AAV (rAAV) vector
technology to deliver a DNA sequence that encodes a soluble form of
the TNF-alpha receptor (TNFR:Fc). Soluble TNFR inhibits the immune
stimulating activity of TNF-alpha. Direct injection of tgAAC94 into
affected joints leads to the localized production of soluble TNFR
within joint cells, reducing the activity of TNF-alpha within the
joint and, potentially, leading to a decrease in the signs and
symptoms of inflammatory disease and inhibition of joint
destruction. The Company's rAAV technology platform is used to
deliver genes and is based on AAV, a naturally occurring virus that
has not been associated with any disease in humans. About Targeted
Genetics Targeted Genetics Corporation is a biotechnology company
committed to the development and commercialization of innovative,
targeted molecular therapies for the prevention and treatment of
inflammatory arthritis, HIV/AIDS and other acquired and inherited
diseases with significant unmet medical need. Targeted Genetics
uses its considerable knowledge and capabilities in the development
and manufacturing of gene delivery technologies to advance a
diverse product development pipeline. Its product development
efforts target inflammatory arthritis, HIV/AIDS, congestive heart
failure, Huntington's disease, and hyperlipidemia. To learn more
about Targeted Genetics, visit its website at
www.targetedgenetics.com. Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995: This release contains
forward-looking statements regarding our potential development
platforms, our ability to commercialize any of our products in
clinical trials, including tgAAC94, our ability to produce our
products at large scale commercial production and other statements
about our plans, objectives, intentions and expectations. These
statements, involve current expectations, forecasts of future
events and other statements that are not historical facts.
Inaccurate assumptions and known and unknown risks and
uncertainties can affect the accuracy of forward-looking
statements. Factors that could affect our actual results include,
but are not limited to, results of animal research are not
necessarily indicative of results in humans, the timing, nature and
results of our research, potential development of alternative
technologies or more effective products by competitors, our ability
to recruit and enroll suitable trial participants, our ability to
obtain and maintain regulatory or institutional approvals, our
ability to obtain, maintain and protect our intellectual property
and our ability to raise capital when needed, as well as other risk
factors described in Item 1A. Risk Factors in our report on Form
10-K for the year ended December 31, 2005 and updated in Item 1A.
Risk Factors in our Form 10-Q for the quarter ended March 31, 2006.
You should not rely unduly on these forward-looking statements,
which apply only as of the date of this release. We undertake no
duty to publicly announce or report revisions to these statements
as new information becomes available that may change our
expectations.
Targeted Genetics (NASDAQ:TGEND)
過去 株価チャート
から 9 2024 まで 10 2024
Targeted Genetics (NASDAQ:TGEND)
過去 株価チャート
から 10 2023 まで 10 2024
Real-Time news about Targeted Genetics Corp (ナスダック市場): 0 recent articles
その他のTargeted Genetics Corporationニュース記事